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1. Introduction 
In recent years, an increasing number of salmonellosis outbreaks have been recorded 
around the world, and probably there should be more cases that were not detected or 
reported (1). Many different types of Salmonella exist, some of which cause illness in both 
animals and people, and some types cause illness in animals but not in people. The various 
forms of Salmonella that can infect people are referred to as serotypes, which are very closely 
related microorganisms that share certain structural features. Some serotypes are only 
present in certain parts of the world (1). Salmonella spp are gram negative anaerobic and 
intracellular bacteria. Salmonellosis, mainly due to Salmonella typhimurium, occurs more 
frequently in HIV-infected patients than in healthy individuals and the frequency of 
bacteraemia is much higher in such patients (2). 
Despite the discovery of new antibiotics, treatment of intracellular infections often fails to 
eradicate the pathogens completely. One major reason is that many antimicrobials are 
difficult to transport through cell membranes and have low activity inside the cells, thereby 
imposing negligible inhibitory or bactericidal effects on the intracellular bacteria (3). In 
addition, antimicrobial toxicity to healthy tissues poses a significant limitation to their use 
(3). Therefore, the delivery of the drug to the bacterial cells is currently a big challenge to the 
clinicians. This is on top of the problems posed by the emerging Multi-Drug Resistant 
species. Moreover, the reduced membrane permeability of microorganisms has been cited as 
a key mechanism of resistance to antibiotics (4).  
Indeed, the challenge is to design the means of carrying an antibiotic into bacterial cells. 
The pioneer concept of targeted drugs was developed by Ehrlich in 1906 and defined as 
the ‘magic bullet’. Since then targeted drug delivery has involved design and 
development of small molecule drugs that can specifically interact with the intended 
receptors in intended tissues. For example prodrugs can be designed for brain delivery of 
the active drug (5). Another common example is colon delivery of prodrugs designed to 
release the drug by taking advantage of the bacterial reductase enzymes in colon (6). 
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However, the drug development process is inevitably lengthy and breakthroughs are 
quite scarce which has led to the ever increasing cost of discovery and development of 
new drugs (7). On the other hand, nanotechnology offers a more convenient method for 
targeted therapy.  
Logistic targeting strategies can be employed to enable the drug to be endocytosed by 
phagocytic cells and then released into the bacteria. To reach the above goal, a drug carrier is 
generally needed for a drug to arrive at the target site (8). The first study employing a drug 
carrier for targeted drug delivery was published approximately 40 years ago, using antibodies 
as carriers of radioactivity for the specific recognition of tumor cells (9). The ideal drug carrier 
ensures the timely release of the drug within the therapeutic window at the appropriate site, is 
neither toxic nor immunogenic, is biodegradable or easily excreted after action, and is 
preferably cheap and stable upon storage (10). Out of different types of drug carriers that have 
been investigated, many are soluble macromolecular carriers or liposomes (11-15).  
By searching all published work on drug carriers it can be concluded that ''the ideal drug 
carrier" does not exist. The suitability of a drug carrier is determined by the disease that will 
be targeted, its access to the pathological site, and the carriers’ ability to achieve appropriate 
drug retention and timely drug release (16). When these types of formulations are 
administered by the intravenous route, phospholipidic, polymeric or metal particles are 
localized preferentially in organs with high phagocytic activity and in circulating 
monocytes, ensuring their clearance (8). The ability of circulating carriers to target these cells 
is highly dependent on tissue characteristics and on the carrier’s properties. The liver rather 
than the spleen or bone marrow captures the submicronic particles (8). Immediately after 
injection, the foreign particles are subjected to opsonization by plasma proteins. This is the 
process by which bacteria are altered by opsonins so as to become more readily and more 
efficiently engulfed by phagocytes. In this way, ‘classical’ or ‘conventional’ carriers are 
recognized by the mononuclear phagocytic system (8). 
The approaches for drug carrier to improve the drug’s antibacterial efficacy are shown in 
Figure 1. In most cases, i.v. administration of the formulation is needed particularly for 
passive and active targeting. 
The local administration of drug/carriers will increase the residence time of antibiotics at the 
site of infection (17-19). These carriers are generally investigated with the intention to treat 
local infections in body parts with limited blood flow as in bone, joint, skin, and cornea.  
In passive targeting after i.v. administration of carriers which tend to be taken by phagocytic 
cells, drug-carrier complex will target intracellular infections. These infections are often 
difficult to treat as a result of limited ability of the antimicrobial agent to penetrate into cells. 
This approach makes use of the recognition of drug carriers (nanoparticles) as foreign 
material in the bloodstream by the phagocytic cells of the mononuclear phagocyte system, 
the cell type often infected with microorganisms (20, 21). 
Regarding the other two approaches (passive targeting with long-circulation time, and 
active targeting) the targeting of infectious foci is not restricted to mononuclear phagocyte 
system tissues. In passive targeting a drug carrier with long duration of circulation is used 
and this is an area which has extensively been investigated, whereas in active targeting 
carriers specifically bind to the infectious organism or host cells involved in the 
inflammatory response.  
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Fig. 1. Drug carrier approaches targeting bacterial infections to improve antibacterial 
efficacy of drugs. 
This chapter focuses mainly on the current research for increasing anti-salmonella 
performance of antibiotics by means of liposomes and nanoparticle systems. Structure, 
properties, advantages and disadvantages of these drug delivery systems have been 
discussed. It is clear that such systems may improve the antibiotic efficacy by increasing the 
drug concentration at the surrounding of the bacteria. 
2. Liposomes for antisalmonellosis drug delivery 
2.1 Introduction 
Liposomes are composed of small vesicles of a bilayer of phospholipid, encapsulating an 
aqueous space ranging from about 30 to 10000 nm in diameter (Figure 2). They are 
composed of one or several lipid membranes enclosing discrete aqueous compartments. 
The enclosed vesicles can encapsulate water-soluble drugs in the aqueous spaces, and 
lipid soluble drugs can be incorporated into the membranes. They are used as drug 
carriers in the cosmetic and pharmaceutical industry. The main routes of liposome 
administration are parenteral, topical and inhalation, and, in a few occasions, possibly 
other routes of administration can be used. Majority of current products are administered 
parenterally (22). 
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Liposome structure was first described in 1965, and they were proposed as a drug 
delivery nanoparticle platform in 1970s. In 1995, Doxil (doxorubicin liposomes) became 
the first liposomal delivery system approved by the Food and Drug Administration (FDA) 
to treat AIDS associated Kaposi’s sarcoma (23). Liposomal drug delivery systems can be 
made of either natural or synthetic lipids. The main building blocks of some liposomal 
formulations are phospholipids (22). These are natural biomacromolecules that play a 
central role in human physiology as they are structural components of biological 
membranes and support organisms with the energy (24). They are amphiphilic molecules, 
poorly soluble in water, consisting of a hydrophilic part containing hydroxyl groups (the 
polar head), a glycerol backbone and two fatty acid chains, which form the hydrophobic 
part. One of the most commonly used lipids in liposome preparation is 
phosphotidylcholine, which is an electrically neutral phospholipid that contains fatty acyl 
chains of varying degrees of saturation and length. Cholesterol is normally incorporated 
into the formulation to adjust membrane rigidity and stability (8). Liposomes can be 
characterized in terms of size and lamellarity as small unilamellar vesicles (SUV), large 
unilamellar vesicles (LUV) and multi lamellar vesicles (MLV). MLVs are usually 
considered large vesicles and aqueous regions exist in the core and in the spaces between 
their bilayers. The structure of these liposomes is shown in Figure 2.  
 
 (a)    (b)  
Fig. 2. Schematic structures of (a) multilamellar and (b) unilamellar liposomes (the picture 
was taken from http://what-when-how.com/nanoscience-and-
nanotechnology/nanoencapsulation-of-bioactive-substances-part-1-nanotechnology). 
The main advantages of liposomes as drug delivery systems can be in their versatile 
structure that can be easily modified according to experimental needs; they can also 
encapsulate hydrophilic drugs in their aqueous compartments and hydrophobic drugs in 
their bilayers, while amphiphilic drugs will be partitioned between the two. Moreover, 
being mainly made of phospholipid, they are non-toxic, non-immunogenic and fully 
biodegradable. Methods for preparing liposomes can take into consideration parameters 
such as the physicochemical characteristics of the liposomal ingredients, materials to be 
contained within the liposomes, particle size, polydispersity, surface zeta potential, shelf 
time, batch-to-batch reproducibility, and the possibility for large-scale production of safe 
and efficient products (23). 
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2.2 Preparation of liposoms 
Liposome formation happens spontaneously when phospholipids are dispersed in water. 
However, in order to obtain the desired formulation with particular size and structure, 
various methods such as thin film method (24), sonication (25), extrusion (26), injection 
methods (27), dehydrated-rehydrated vesicles (28), reverse phase evaporation (29) and one 
step method (30) have to be used. 
Each technique is briefly described below, but for more details, it is recommended to refer to 
the cited references. In brief, in thin film method liquids are dissolved in organic solvents 
and the solvent is removed under vacuum or nitrogen stream to form a thin film on the wall 
of a flask or test tube. In order to complete the formation of liposomes aqueous phase is 
added to the lipid film at a temperature above the phase transition of the lipid (24).  
The sonication method is usually used to reduce the particle size and lamellarity of MLVs. In 
case of using the probe sonicator, the reduction in size of the liposomes can be guaranteed (25).  
In order to get very homogeneous vesicles with a predetermined size, the extrusion 
technique is used. MLVs are extruded under pressure through particular filter with well-
defined pore sizes from 30 nm to several micrometers. If the extrusion is repeated several 
times unilamellar liposomes can be formed (26). 
Very small unilamellar vesicles with a particle size of 30 nm can be prepared using the 
ethanol injection method. Generally, lipids are dissolved in ethanol and injected rapidly into 
the aqueous solution, under stirring. At the end, the injected ethanol has to be removed 
from the system (27). 
As dehydrated-rehydrated vesicles are able to hold high amounts of hydrophilic drugs 
under mild conditions, therefore this method is suitable for the drugs that are losing their 
activity under harsh conditions (28). Empty liposomes, usually unilamellar vesicles, are 
disrupted during a freeze drying step in the presence of the drug meant to be encapsulated. 
A controlled rehydration is obtained in the presence of concentrated solution of the drug. 
This technique can produce large oligolamellar liposomes of a size around 400 nm to several 
micrometers. It has been shown that in case of producing smaller liposomes (100-200 nm) 
sucrose can be added (31).  
In the reverse phase evaporation technique which is similar to thin film technique, lipids are 
dissolved in organic solvent and the solvent is removed by evaporation (29). The thin film is 
resuspended in diethyl ether followed by the addition of third of water and the suspension 
is sonicated in a bath sonicator. The emulsion is evaporated until a gel is formed and finally 
the gel is broken by the addition of water under agitation. The traces of organic solvent 
should be removed by evaporation (29). 
Finally, in the one-step method, lipid dispersion should be hydrated at high temperatures 
under nitrogen gas stream. This method has the capability to produce liposomes in the 
range of 200-500 nm (30).  
2.3 Targeted delivery by liposomes 
The main methods of delivery from liposome to cytoplasm include the exchange of 
membrane and lipids, contact release, adsorption, fusion and endocytosis. Through these 
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processes, drugs can be released into the bacterial or eukaryotic cells. Liposomal 
formulations have been used for the delivery of antitumor anthracyclines such as 
doxorubicin (23) and antifungal agent amphotericin B. Targeted delivery of liposomes to 
tumor cells has been explored through arsenoliposomes (32). Liposomes for antibacterial 
chemotherapy are under intensive research to enhance the antibacterial activity and 
improve pharmacokinetic properties. Advantages of liposomal antibiotics include improved 
pharmacokinetics, decreased toxicity, enhanced activity against intracellular pathogens, 
target selectivity and as a tool to overcome bacterial drug resistance (3).  
Some liposomes are unique because they can be selectively absorbed by tissues rich in 
reticuloendothelial cells, such as the liver, spleen and bone marrow. This can serve as a 
targeting mechanism, but it also removes liposomes from the circulation rather rapidly. 
Although the poor stability of liposomes, particularly the rapid uptake from the body is not 
desirable, it could be useful for eradicating the infection by ‘passive targeting’ through 
macrophage activation and killing or elimination of parasitic infections.  
On the other hand, surface charge and phospholipid composition can affect the interactions 
of liposomes with bacterial cell surface. For example it has been shown that cationic 
liposome formulations are more efficient in binding to skin bacterial cells (33). 
Moreover, by attaching targeting ligands such as immunoglobulines (34), antibody segments, 
aptamer (35), peptides and small molecule ligands, and oligosaccharide chains (36), to the 
surface of the liposomes, they can selectively bind to microorganisms or infected cells and then 
release the drug payloads to kill or inhibit the growth of the microorganisms (23). The highly 
specific liposomes are those containing antibodies or immunoglobulin fragments which have 
affinity to specific receptors on the surface of the infected tissue cells or pathogens (3). 
Biofilm surface characteristics have also been used for targeted delivery. Biofilms are 
microbial aggregations that are covered in an extracellular matrix of polymeric substances. 
The matrix is usually composed of complex mixture of oligomeric and polymeric molecules 
such as proteins, lipids and polysaccharides which, as Microbial Associated Molecular 
Patterns (MAMPs), elicit host defenses (37). Pathogens are much more difficult to control 
when living in biofilms. This is partly due to the matrix preventing drug transport to the 
microbial cells. Moreover, bacteria in biofilms grow slower and have reduced metabolic 
activity, and therefore they are expected to be less susceptible to the antibiotics (38). 
Currently a great deal of research is focused on exploring new chemotherapeutic targets in 
biofilms (37). On the other hand liposomes have proven efficient in targeting and 
eradication of various types of biofilms. Examples are immunoliposomes with high affinity 
to various oral bacteria including Streptococcus oralis (34) and polysaccharide-coated 
liposomes for the efficient delivery of metronidazol to periodontal pocket biofilm (39).  
pH-sensitive liposomes offer another method for targeting and efficiently delivering the 
liposomal content into cytoplasm. Such liposomes are stable at physiological pH but 
undergo destabilization under acidic conditions. Therefore, they are able to promote fusion 
of target plasma or endosomal membranes, the so called ‘fusogenic’ properties, at acidic pH 
(40). Several mechanisms can trigger pH-sensitivity in liposomes. One of the most widely 
used methods is the use of a combination of phosphatidylethanolamine (PE) or its 
derivatives with compounds containing an acidic group that act as a stabilizer at neutral pH 
(41). Other more recent methods include the use of novel pH-sensitive lipids, synthetic 
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fusogenic peptides/proteins (42) and association of pH-sensitive polymers with liposomes 
(43). pH-sensitive liposomes have found applications in many therapeutic area including the 
antibiotic delivery to intracellular infections (44). 
2.4 Pharmacokinetics consideration of liposomal drug delivery 
Liposomal carriers can lead to sustained release of antibiotics during drug circulation in the 
body. Thus, appropriate levels of drug will be available for a longer duration in comparison 
with the conventional antibiotic formulations where the outcome is a quick and short effect 
(45). However, conventional liposomes are quickly opsonized after intravenous administration 
and therefore they are taken up by the mononuclear phagocyte as foreign antigens. As a 
consequence blood circulation time is lowered. By controlling the physicochemical properties 
of the vesicles (size and charge distribution, membrane permeability, tendency for aggregation 
or fusion, drug encapsulation efficiency, membrane rigidity) and therefore their interaction 
with the biological environment, many different types of liposomes with the aim of obtaining 
longer circulation half-lives can be developed (8).  
The plasma circulation time of antibiotics can be improved by encapsulation in polyethylene 
glycol-coated (pegylated) (STEALTH) liposomes. The PEG coating forms a hydration layer 
that retards the reticuloendothelial system recognitions of liposomes through sterically 
inhibiting hydrophobic and electrostatic interactions with plasma proteins (46). Other 
methods that can confer hydrophilicity or steric repulsion are by the use of compounds 
having sialic residues, or through MLVs containing phospholipids with long saturated 
chains and negative surface charge (47). The increased half lives of stealth liposomes 
increase their ability to leave the vascular system into some extravascular regions. 
2.5 Antibiotic loaded liposomes against Salmonella spp 
One of the distinguishing features of liposomes is their lipid bilayer structure, which 
mimics cell membranes and can readily fuse with the cell membrane and deliver the 
antibiotic contents into the cellular cytoplasm. As a result, drug delivery may be 
improved to bacterial and eukaryotic cells alike. By directly fusing with bacterial 
membranes, the drug payloads of liposomes can be released into the cell membranes or to 
the interior of the bacteria. In terms of extracellular pathogens, improved antibiotic 
delivery into the bacterial cells is of particular importance especially since it can interfere 
with some of the bacterial drug-resistance mechanisms which involve low permeability of 
the outer membrane or efflux systems (48). 
Liposomes are particularly successful in eradicating intracellular pathogens. Examples of 
these include liposomal formulations of antituberculosis agents isoniazid and rifampin 
(49), and ampicillin loaded liposomes for eradication of Listeria monocytogenes (50). This 
is partly due to improved drug retention in the infected tissue and the decreased toxicity 
as a result of sustained release of drug from liposomes. Moreover, liposomal formulations 
often have improved antibiotic pharmacokinetics with extended circulation time and 
prolonged tissue retention.  
Liposomal chemotherapeutics for the treatment of salmonellosis may employ some of the 
conventional antibiotics with proven inhibitory or cidal activity in vitro. Bacterial gastro-
intestinal infections with Salmonella typhi may be treated with chloramphenicol. Alternatives to 
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chloramphenicol include amoxicillin, co-trimoxazole and trimethoprim (51). Recently 
treatment with cephalosporins and fluoroquinolones has become popular, as several members 
of these antibiotic families have been shown to be effective. The treatment of paratyphoid fever 
is the same as that for typhoid (51). Salmonella food-poisoning is self-limiting and does not 
require antibiotic therapy, unless the patient is severly ill or blood cultures indicate systemic 
infection. In this case, third generation cephalosporins or fluoroquinolones are the most 
reliable agents (51). Ceftriaxone or a first generation fluoroquinolone such as ciprofloxacin, 
ofloxacin or pefloxacin but not norfloxacin have been recommended as the first choice in 
typhoid and paratyphoid by The Sanford Guide to Antimicrobial Therapy (52). The improved 
efficiency of liposome formulations of antibiotics has been shown in vitro and in vivo. The in 
vitro infection models utilize macrophages infected with salmonella. 
2.5.1 Penicillin loaded liposomes 
The tissue distribution of ampicillin loaded liposomes was studied in normal noninfected 
mice and showed that ampicillin concentrated mostly in the liver and spleen (53). The 
Liposome formulation of ampicillin was significantly more effective than free ampicillin in 
reducing mortality in acutely infected mice with Salmonella typhimurium C5. These 
liposomes were quite efficient in targeting ampicillin to the spleen but were less effective in 
targeting ampicillin to the liver and reducing mortality in acute salmonellosis (53). 
2.5.2 Cephalosporine loaded liposomes 
Third generation cephalosporines have been indicated as suitable candidates for the 
treatment of Salmonella infections (52). Liposome formulations of these antibiotics may 
improve pharmacokinetics and also the targeted delivery to the intracellular infections. In a 
study with cephalotin, treatment of infected macrophages with multilamellar liposome-
encapsulated cephalothin enhanced the intraphagocytic killing of Salmonella typhimurium 
over that by macrophages treated with free cephalothin (54). Resident murine peritoneal 
macrophages were shown to be capable of interiorizing the liposome-antibiotic complex 
leading to a relatively high intracellular concentration of cephalothin. The intracellular 
killing of the bacteria was maximal at 60 min of incubation; at this time, 60% of the 
interiorized organisms had been killed (54).  
Desiderio & Campbell infected mice with Salmonella typhimurium to investigate the 
effectiveness of liposome-encapsulated cephalothin treatment (55). In the study they also 
compared the results with formulations containing free cephalothin. They showed that 
following intravenous administration, liposome-encapsulated cephalothin was cleared from 
the circulation more rapidly and concentrated in the liver and spleen. Treatment of infected 
mice with the liposome antibiotic complex was more efficacious in terms of reducing the 
number of Salmonella typhimurium in these organs compared to the injection of free 
antibiotic, although treatment did not completely eliminate the bacteria from this site (55). 
Another study showed that egg phosphatidylcholine liposomes containing cephapirin were 
relatively stable in serum, and provided acceptable serum levels of cephapirin for 24 hr after 
i.v. administration while free drug at a similar dosage was undetectable in 3-5 hr. Moreover, 
the liposome formulation, as opposed to the free drug, could be used successfully for 
prophylaxis. Cephapirin activity in the spleen and liver was greatly increased and persisted 
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for at least 24 hr when iv injections of the liposome formulation was used. This formulation of 
liposome, in contrast with the other liposome formulation containing tris salt of cholesterol 
hemisuccinate, could prolong survival in mice infected with Salmonella typhimurium (56). 
Ceftiofur sodium is a third generation broad spectrum cephalosporin widely used clinically 
to treat respiratory diseases and mastitis. Its spectrum also covers Salmonella spp. The 
liposome formulations of ceftiofur were prepared in order to increase drug half life in vivo 
for veterinary purposes (57). The pharmacokinetic study in healthy cows showed that 
liposome preparations provided therapeutically effective plasma concentrations for a longer 
duration (elimination half life of more than double) than with the drug alone. These 
liposomes were stable and the minimum inhibitory concentrations against Salmonella 
enteritidis were 1⁄4th that of free ceftiofur sodium (57). 
2.5.3 Aminoglycoside loaded liposomes 
Despite the susceptibility of Salmonella spp to aminoglycosides, their use against many 
important intracellular bacterial infections has been limited due to the cell membrane 
permeability problems. Lutwyche et al. prepared several liposomal encapsulation 
formulations including pH-sensitive DOPE-based carrier systems containing gentamicin in 
order to achieve intracellular antibiotic delivery and therefore increase the drug’s 
therapeutic activity against intracellular pathogens (58). They reported the superiority of 
some of the pH-sensitive liposomes over conventional liposome formulations, which was 
associated with the intracellular delivery of the antibiotic and was dependent on endosomal 
acidification. This liposomal carrier demonstrated pH-sensitive fusion that was dependent 
on the presence of unsaturated phosphatidylethanolamine (PE) and the pH-sensitive lipid 
N-succinyldioleoyl-PE. These formulations also efficiently eliminated intracellular infections 
caused by a recombinant hemolysin-expressing Salmonella typhimurium strain which escape 
the vacuole and reside in the cytoplasm. Moreover, in vivo pharmacokinetics and 
biodistribution tests confirmed that encapsulation of gentamicin in pH-sensitive liposomes 
significantly increased the concentrations of the drug in plasma compared to those of free 
gentamicin. Furthermore, liposomal encapsulation increased the levels of accumulation of 
drug in the infected liver and spleen by 153- and 437-folds, respectively (59).  
Other investigations have indicated that even with conventional liposomes, liposome 
encapsulated gentamicin is less toxic in mice than is free gentamicin and is extremely 
effective-therapy for disseminated Salmonella infections in mice. For example when 
gentamicin sulfate was encapsulated in liposomes composed solely of egg 
phosphatidylcholine, the mean half-lives of the encapsulated drug in serum were around 
four times that of free (nonencapsulated) gentamicin in mice and rats following i.v. 
administration. Moreover, liposome encapsulation led to higher and more prolonged 
activity in organs rich in reticuloendothelial cells especially in spleen and liver. In acute 
septicemia infections in mice, the liposomal formulation showed enhanced prophylactic 
activity when compared with the free drug. In a model of murine salmonellosis, liposomal 
gentamicin greatly enhanced the survival rate (60). Similarly, a single iv injection of low 
dose gentamicin loaded multilamellar liposomes (composed of egg phosphatidylcholine, 
egg phosphatidylglycerol, cholesterol and alpha-tocopherol) resulted in 80% survival of 
mice infected with Salmonella Dublin, while zero survival was observed when treated with 
the same amount of free gentamicin. Higher concentrations of free gentamicin led to 
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neuromuscular paralysis, while the slow release of this dose from liposomes increased the 
survival rate to 100%. After the single dose treatments with liposomes, high concentrations 
of the drug were detectable for 10 days (61). The liposome-encapsulated gentamicin has also 
been proven successful in the treatment of Mycobacterium Avium-M intracellular complex 
(MAC) bacteremia in AIDS patients. In this case, MAC colony counts in blood fell by 75% or 
more when given intravenously twice weekly for 4 weeks (62).  
Another effective antibiotic for liposomal formulation which attracted the interest of 
researchers is streptomycin. Conventional liposomal formulation of streptomycin made with 
egg yolk phosphatidylcholine was investigated using in vivo model of Salmonella infection in 
mice. Liposome-entrapped streptomycin prolonged the survival to more than 15 days for all 
mice infected with the virulent strain of Salmonella enteritidis, while treatment with the same 
dose of free streptomycin resulted in all of the mice dying between days 5 and 7. The 
prolongation of survival was due to suppression of the multiplication of S. enteritidis. 
Furthermore, the liposome-entrapped drug was less toxic than the free drug when applied at 
high doses. A tissue distribution study in various organs demonstrated that liposomal 
streptomycin was selectively accumulated in the spleen and liver with concentrations in these 
organs about 100 times higher than those in mice receiving the free drug (63). 
In contrast to this, another investigation on S. enteritidis indicated a less concentration of 
streptomycin administered using some of the liposome formulations in the liver and spleen in 
comparison with the free drug (9). In this study, several formulations of streptomycin sulfate 
liposomes, prepared from a mixture of L-a-dipalmitoy phosphatidyl choline (DPPC) and 
cholesterol with or without a charge inducing agent, were used in drug targeting experiments 
using Swiss mice. The biodistribution results indicated that although, in comparison with the 
free drug, some of the liposome formulations exhibited 2-3 times higher concentration of 
streptomycin in the liver and spleen, this effect decreased over time from one to seven days. 
Despite this, the survival rate experiments indicated a definite protection against Salmonella 
enteritidis exhibited by the liposome-encapsulated streptomycin compared to the free drug 
(64). Therefore, it seems that the liposome formulation plays the major role in the targeting 
effect and the delivery efficiency of the liposomes for intracellular infections.  
2.5.4 Fluoroquinolone loaded liposomes 
Ciprofloxacin is a synthetic bactericidal fluoroquinolone which inhibits the activity of 
bacterial DNA gyrase, resulting in the degradation of bacterial DNA by exonuclease 
activity. Consequently, ciprofloxacin has broad-spectrum efficacy against a wide variety of 
bacteria, including the family Enterobacteriaceae of which Salmonella spp is a member of (65). 
It has been used in the treatment of individuals with Salmonella infections, including those 
with typhoid fever and chronic typhoid carriers (52). Despite the enormous success with 
ciprofloxacin, there are some factors which limit the drug’s clinical utility, such as its poor 
solubility at physiological pH and rapid renal clearance. Several investigations have focused 
on the formulation of this drug as liposomes, in order to improve the drug delivery.  
Ciprofloxacin loaded liposomes, consisting of dipalmitoyl-phosphatidylcholine, 
dipalmitoyl-phosphatidylglycerol and cholesterol, were used to treat Salmonella Dublin 
infected mice (66). It has been reported that a single injection of liposome formulation was 
10 times more effective than a single injection of free drug at preventing mortality. 
Treatment with liposomal ciprofloxacin produced dose-dependent decreases in bacterial 
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counts in spleen, stool, and Peyer's patches, indicating that the drug had distributed to all 
areas of inflammation, not just to the major reticuloendothelial system organs. Although 
liposome formulation was cleared rapidly from the blood, drug persisted in the liver and 
spleen for at least 48 h after administration of a dose (66).  
In a similar study, Webb et al. encapsulated ciprofloxacin into large unilamellar liposomes. 
The LUVs composed of dipalmitoylphosphatidylcholine-cholesterol, distearoylpho-
sphatidylcholine-cholesterol, or sphingomyelin-cholesterol. In comparison with the free 
drug, the liposomal formulations increased the circulation lifetime of the drug by >15 fold 
and resulted in 103 to 104 fold fewer viable Salmonella typhimurium in the livers and spleens 
after intravenous administration (67). These results show the utility of liposomal 
encapsulation in improving the pharmacokinetics, biodistribution, and antibacterial efficacy 
of ciprofloxacin. 
3. Polymeric nanoparticles for antisalmonellosis drug delivery 
3.1 Introduction 
Nanoparticles (NP) are solid colloidal particles with particle sizes smaller than 1000 nm. 
However, most nanoparticles utilized in drug delivery are in the size range of 100–200 nm. 
Nanoparticles can be classified into two main subgroups: nanospheres and nanocapsules. 
Nanospheres have a matrix-type structure, and drug molecules can be adsorbed on their 
surface or entrapped inside their matrix. Nanocapsules have a capsule-like structure and 
possess the capability of encapsulating the drug molecules inside the capsule or adsorbed to 
them externally. Because these systems have unique characteristics, such as very small 
particle size, high surface area, and possibility of surface modification, they have been 
attracting much interest for drug-delivery purposes during recent years. Nanoparticles are 
able to adsorb and/or encapsulate a drug, thus protecting it against chemical and enzymatic 
degradation. Generally, the drug is dissolved, entrapped, encapsulated or attached to a NP 
matrix and depending upon the method of preparation, nanoparticles, nanospheres or 
nanocapsules can be obtained. Owing to their polymeric nature, nanoparticles (Figure 3) 
may be more stable than liposomes in biological fluids and during storage.  
 
(a)     (b) 
Fig. 3. Schematic structures of (a) nanosphere and (b) nanocapsule type nanoparticles (the 
picture was taken from http://what-when-how.com/nanoscience-and-
nanotechnology/nanoencapsulation-of-bioactive-substances-part-1-nanotechnology).  
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Nanocapsules are vesicular systems in which the drug is confined to a cavity surrounded by 
a unique polymer membrane, while nanospheres are matrix systems in which the drug is 
physically and uniformly dispersed. In order for nanoparticles to minimize the side effects, 
the polymers associated with nanoparticles must be degraded in vivo due to intracellular 
polymeric overloading. Thus in recent years, biodegradable polymeric nanoparticles have 
attracted considerable attention as potential drug delivery devices in view of their 
applications in the controlled release of drugs, their ability to target particular organs, as 
carriers for DNA in gene therapy, and their ability to deliver proteins, peptides and genes 
through a peroral route of administration (68). Most polymers PLGA, chitosan, gelatin, 
alginate, and poly cyanoacrylate can be used in the formulation of nanoparticles.  
It is believed that nanoparticles could be effective in increasing drug accumulation at the site 
of infection with reduced toxicity and side effects after parenteral or oral administration (69, 
70). Polymeric nanoparticles have been explored to deliver a variety of antimicrobial agents 
to treat various infectious diseases and have shown great therapeutic efficacy (71).  
3.2 Antibiotic loaded cyanoacrylate nanoparticles 
The polymers involved in nanoparticle structure should be degraded in order to release the 
drug, therefore, there should be a direct correlation between the rate of degradation and the 
drug release rate. If degradation happens in the presence of esterase, it was shown that the 
degradation of the polymer in esterase-free medium is low, therefore, the drug release rate 
is low accordingly. The drug release was increased when the medium contained 
carboxyesterase (72).  
The in vitro interaction between [3H]ampicillin-loaded polyisohexylcyanoacrylate 
nanoparticles and murine macrophages infected with Salmonella typhimurium was investigated 
and the results showed that the uptake of nanoparticle-bound [3H]ampicillin by non-infected 
macrophages was six- and 24-fold greater respectively compared to free [3H]ampicillin. 
However, there was no difference between nanoparticle-bound ampicillin and free ampicillin 
in terms of bactericidal activity against intracellular Salmonella typhimurium. This unexpected 
observation might be accounted for by bacterium-induced inhibition of phagosome-lyosome 
fusion within the macrophages, thereby preventing contact between the bacteria in the 
phagosomes and the nanoparticles in the secondary lysosomes (73). 
In another study the intracellular distribution of (3H)ampicillin-loaded 
polyisohexylcyanoacrylate nanoparticles in the same cells using ultrastructural 
autoradiography was investigated by the same authors (74). Ampicillin penetration and 
retention into the cells obviously increased by means of nanoparticles. After 2-4 h treatment 
with the nanoparticle formulation, numerous intracellular bacteria were seen to be in the 
process of destruction. After 12 h treatment, numerous spherical bodies and larger forms 
were seen in the vacuoles and it was an indication of marked damaging action of the 
ampicillin on the bacterial walls. The targeting of ampicillin therefore allowed its 
penetration into the macrophages and vacuoles infected with Salmonella typhimurium (74). 
Pinto-Alphandary et al. used transmission electron microscopy to prove that ampicillin 
which usually penetrates into cells at a low level is directly carried in when loaded on 
nanoparticles, and brought into contact with intracellular bacteria (75). They concluded that 
ampicillin loaded polyisohexylcyanoacrylate nanoparticles is an ideal formulation when an 
intracellular targeting for ampicillin is needed. 
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Page-Clisson et al. (76) investigated the antibacterial efficiency of polyalkylcyanoacrylate 
nanoparticles loaded with ciprofloxacin and ampicillin against Salmonella typhimurium. It 
was shown that in vivo treatment with ciprofloxacin led to a significant decrease of bacterial 
counts in the liver whatever the stage of infection and the form used. However, none of the 
treatments were able to sterilize the spleen or the liver (76). 
Ampicillin was also attached to nanoparticles of polyisohexylcyanoacrylate (PIHCA) for the 
treatment of C57BL/6 mice experimentally infected with Salmonella typhimurium C5. The 
injection of the nanoparticles containing ampicillin treated all mice, whereas by the injection 
of non-loaded nanoparticles all mice died within 10 days (77).  
3.3 Antibiotic loaded PLGA nanoparticles 
Some polymeric nanoparticles may be more effective than liposomes in acute salmonellosis 
model due to better stability of nanoparticles in serum compared to liposomes. Therefore it 
is believed that antibiotic loaded nanoparticles can improve the targeting, particularly in the 
case of intracellular bacteria. For example, gentammicin (78), azithromicin and 
clarithromicin loaded nanoparticles using poly(lactide-co-glycolide) [PLGA] (79, 80) were 
more effective than corresponding intact drug against Salmonella typhimurium.  
As mentioned before, nanoparticles should be degraded in vivo to avoid side effects and it 
has been shown that PLGA nanoparticles fulfill such requirements. Therefore, in most cases 
for antibiotics such as rifampcin (81), amphotericin (82), azithromycin (79) and 
clarithromycin (80) PLGA nanoparticle preparations have been recomended. 
Mohammadi et al., showed that azithromycin and clarithromycin-loaded (PLGA) 
nanoparticles (NPs) prepared with three different ratios of drug to polymer have better 
antibacterial activity against Salmonella typhi (79). In other words, the nanoparticles were more 
effective than pure azithromycin and clarithromycin against Salmonella typhi and S. aureus, 
respectively, with the nanoparticles showing equal antibacterial effect at 1/8 concentration of 
the intact drug. Both studies on azithromycin and clarithromycin proved that the antibacterial 
activity of nanoparticles were about 8-fold more than the free azithromycine and 
clarithromycin (Figure 4). The higher antibacterial effect of clarithromycin and azithromycin 
may have resulted from higher bacterial adhesion of the nanoparticles. For example, an 
adhesion of Eudragit nanoparticles containing PLGA to the S. aureus bacteria was reported 
(83). Although, Figure 4 shows that the ratio of drug:PLGA has no significant effect on 
antibacterial activity of azithromycin and clarithromycin, Table 1 shows that the particle size of 
nanoparticles, their zeta potential and the encapsulation efficiency are remarkably dependent 
on the ratio of drug:polymer used in the formulations. This indicates that by controlling the 
ratio of drug:carrier the desirable particle size and zeta potential could be achieved. As it is 
shown in Figure 5 all nanoparticles were spherical in appearance.  
Several investigations have shown that nanoparticles could not be very effective on all 
different types of bacteria and that the antibacterial effect depends on bacterial type (84). For 
example, recently Martins et al. evaluated the antibacterial activity of PLGA nanoparticles 
containing violacein against different bacteria (84). Although, they showed that the MIC 
with nanoparticles is 2-5 times lower than free violacein against Staphylococcus aureus, the 
results failed to show any significant activity against Escherichia coli and Salmonella enterica.  
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Formulations 
Encapsulation 
efficiency (%) 
Mean particle size 
(nm) 
Zeta potential 
(mV) 
AZI:PLGA (1:1) 50.5 ± 3.4 252 ± 5 -5.6 ± 2.15 
AZI:PLGA (1:2) 66.8 ± 2.8 230 ± 7 -11.10 ± 1.87 
AZI:PLGA (1:3) 78.5 ± 4.2 212 ± 4 -15.56 ± 2.53 
CLR:PLGA (1:1) 57.4 ± 4.3 280 ± 15 -6.3 ± 1.70 
CLR:PLGA (1:2) 72.9 ± 3.2 223 ± 12 -10.08 ± 1.63 
CLR:PLGA (1:3) 80.2 ± 4.0 189 ± 10 -14.26 ± 1.92 
Table 1. Encapsulation efficiency, mean particle size and zeta potential of various formulations 
containing Azithromycine and clarithromycin (data taken from references 79, 80) 
 
Fig. 4. Minimum inhibitory concentrations (MICs) of the intact AZT, CLR, physical mixtures 
(PM) and drug-loaded nanoparticles suspensions with different drug:PLGA ratios (data are 
reproduced from references 79, 80). 
  
(a)     (b) 
Fig. 5. SEM images of clarithromycin and azithromycin-loaded nanoparticles with the ratio 
of drug:PLGA 1:2 (SEM taken from ref. 80). 
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3.4 High loading antibiotic nanoparticles  
One of the problems with antibiotic loaded nanoparticles is that in some cases the capacity 
of a polymeric drug carrier should be engineered to incorporate high concentrations of 
antibiotics to achieve the required dosage, yet avoid side effects that may be associated with 
higher amounts of carriers. This seems a difficult task, however, Ranjan et al introduced two 
novel technologies by which high concentrations of gentamicin could be incorporated into 
the formulations (85). 
In the first technology, Ranjan et al., made an attempt to enhance antibacterial efficacy of 
gentamicin using a new technology called core-shell nanostructures (78). In this research 
pluronic based core-shell nanostructures encapsulating gentamicin were prepared. The 
maximum antibiotic loading was 20% in their formulation with a zeta potential of -0.7. It 
was shown that when using core-shell nanostructures containing gentamicin, not only that 
significant reduction in toxicity and side effects was evident, but also the percentage of 
viable bacteria in the liver and spleen was significantly reduced (78).  
In the second technology, Ranjan et al (85) incorporated gentamicin into macromolecular 
complexes with anionic homo- and block-copolymers via cooperative electrostatic 
interactions between cationic drugs and anionic polymers (Figure 6). They showed the 
possibility of incorporating 26% by weight of gentamicin in the nanoplexes with average 
diameter of 120 nm and zeta potential of -17 (85). This was 6% more drug loading compared 
to their previous study. Their study showed that in addition to the high loading of drug 
carried by these polymeric nanoplexes, the nanoplexes can potentially improve targeting of 
interacellular pathogens such as salmonella.  
 
Fig. 6. (a) Gentamicin is cationic aminoglycoside antibiotic with five amino groups, (b) 
anionic block copolymers for electrostatic complexation to gentamicin, (c) strategy to 
incorporate gentamicin within polymeric nanoplex (Figure was taken from ref 85). 
(a) (b) 
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3.5 Xerogel systems containing antibiotic 
During the last fifteen years, a special attention has been dedicated on silica xerogel 
system to treat diseases due to intracellular pathogens (86-92). The properties of silica 
xerogel systems such as size, zeta potential, pore structure, and the surface characteristics 
make them suitable carriers for therapeutics to target the replicative niche of intracellular 
pathogen. These are ideal systems for the delivery of gentamicin as this antibiotic does not 
kill intracellular Salmonella due to the polar nature of the drug which is associated with 
low level of intracellular penetration. A study showed that when gentamicin was 
incorporated into silica xerogel formulations, 31% of the drug entrapped in the matrix 
system remained biologically active and the bactericidal effect was retained after drug 
release. The results showed that by incorporation of PEG the drug release can be 
modulated. Administration of two doses of the xerogel formulations showed a 
remarkable reduction in the load of Salmonella entrica in the spleen and liver of the 
infected mice (86). A similar study was performed by another group on gentamicin silica 
xerogel systems showing that the silica xerogel was more effective in clearing the 
infection in the liver compared to the same dose of the free drugs (87).  
3.6 Vaccine delivery by polymeric nanoparticles  
Ochoa et al (93) made an attempt to use nanoparticle for the delivery of vaccines. An 
immunogenic subcellular extract obtained from whole Salmonella Enteritidis cells (HE) was 
encapsulated in nanoparticles made with the polymer Gantrez (HE-NP). When they 
studied the immunogenicity and protection of HE-loaded nanoparticles against lethal 
Salmonella Enteritidis in mice, an increase in survival was observed compared to a control 
group (80% of the mice immunized with the HE-loaded nanoparticle formulation 
survived even when administered 49 days before the lethal challenge). They noticed that 
the cytokines released from in vitro-stimulated spleens showed a strong gamma interferon 
response in all immunized groups at day 10 post-immunization. However, the immunity 
induced by HE-loaded nanoparticles at day 49 post-immunization suggests the 
involvement of a TH2 subclass in the protective effect. It can be concluded from their 
study that, HE-nanoparticles may represent an important alternative to the conventional 
attenuated vaccines against Salmonella Enteritidis (93). 
4. Metal nanoparticles as antisalmonellosis agents 
In the fast-developing field of nanotechnology, metal nanoparticles are of great interest due 
to their multiple applications as chemical catalysts, adsorbents, biological stains, and 
building blocks of novel nanometer scale optical, electronic, and magnetic devices. Metal 
nanoparticles are pure metal nano sized material (Figure 7) with the size of usually up to 
200 nm. They have been suggested to be suitable for biological applications. It was shown 
that if the size of these nanoparticles is less than 50 nm they are the most suitable particles as 
therapeutic agents as the biosystem fails to detect them (94). 
Different types of nanometals including copper, magnesium, zinc, titanium, gold, and silver 
have been investigated but silver nanoparticles have been employed and investigated most 
extensively compared to the other metals since ancient times to fight infections and control 
spoilage (95-97). A large number of successful in vitro studies were performed for the 
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evaluation of the antisalmonella effect of metal nanoparticles. These nanoparticles are usually 
nonspecific and are broad spectrum antibacterial. It is also reported that silver can cause 
argyrosis and argyria and is toxic to mammalian cells (98). As silver attacks a broad range of 
targets in the microbes, therefore it is difficult for microbes to develop resistance against silver 
(99). This property of silver makes it an excellent candidate for antimicrobial effect.  
 
Fig. 7. Schematic structure of a metal nanoparticle 
In terms of production, it is suggested that monodispersed particles (very narrow particle 
size distribution) rather than polydispersed nanoparticles (broad particle size distribution) 
are preferred. This is because the former distribution is believed to be more effective against 
microbes due to the high surface/volume fraction so that a large proportion of silver atoms 
can be in direct contact with their environment (100).  
Recently, the potential use of silver nanoparticles on pathogenic bacteria was reviewed (101). 
There are various physical, chemical or biological methods which can be used to produce 
metallic nanoparticles. Among these, it seems, the biological method is popular due to the 
reliability and being eco-friendly. This method has attracted the attention of researchers in the 
field (102-108). In fact, a number of different species of bacteria and fungi are able to reduce 
metal ions producing metallic nanoparticles with antimicrobial properties. Recently, it has 
been shown that silver nanoparticles produced by the fungus F. acuminatum have efficient 
antibacterial activity against multidrug resistant and highly pathogenic, Salmonella typhi (109). 
Additionally, plant extracts can also be used to obtain metallic nanoparticles (110). Metal 
nanoparticles were also modified to be used in the prevention of biofilm formation on the 
implanted devices (111-114), however, care must be taken when this type of metal 
nanoparticles are used due to potential risk on patient’s health (115-117).  
Researchers suggested that to achieve a better utilization of the antimicrobial activity, metal 
nanoparticles may be combined with nontoxic and biocompatible polymers. For example, in 
an attempt NaPGA- (poly (g-glutamic acid)) and CaPGA-coated magnetite nanoparticles 
were synthesized (118) and their antibacterial activity against Salmonella enteritidis, 
Staphylococcus aureous and Eschercia coli were tested. The results showed that both produced 
nanoparticles were more effective against Salmonella enteridis compared to commercial 
antibiotics, linezolid and cefaclor. In addition, these nanoparticles showed no toxicity 
toward human skin fibroblast cells.  
In few cases polymers such as PVP have been used as steric stabilizers to obtain 
monodispersed silver nanoparticles (119, 120). Although silver nanoparticles have the 
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capability to remain dispersed in liquids without major signs of agglomeration, in case of 
the appearance of aggregation hydrophilic surfactants, proteins, amino acids and PVA (poly 
vinyl alcohol) can be used (121-125). Metal nanoparticles have also found application in 
various other fields, i.e. catalysis and sensors as mentioned before (126-128). However, their 
undesirable and unforeseen effects on the environment and in the ecosystem should not be 
ignored (129, 130). The antibacterial effect of silver and copper nanoparticles was also 
investigated on Escherichia coli, Bacillus subtilis and Staphylococcus aureus (131). The results 
showed that the efficiency of silver and copper nanoparticles were different on different 
bacteria. Among the bacteria used, B. subtilis showed the highest sensitivity to copper 
nanoparticles compared to silver, whereas silver nanoparticles were more effective on the 
other two bacteria compared to copper nanoparticels (133).  
Interesting results were reported by Patil et al when they synthesized and tested 
chloramphenicol loaded nano-silver particles against Salmonella typhi (97). For the first time 
they used PVP in their formulations containing silver as a carrier for chloramphenicol. In the 
formulation, PVP played a dual role. It acts as a stabilizer and linker for binding 
chloramphenicol to the silver nanoparticles (Figure 8). The nanoparticles showed 
considerably enhanced activity against clinically isolated Salmonella typhi. 
 
Fig. 8. Top: schematic representation of the synthesis of silver nanoparticles (PVP as a 
stabilizer); bottom: schematic representation of the synthesis of chloramphenicol loaded 
silver nanoparticles (PVP as a linker) (figure was reproduced from ref 97). 
The summary of some of metal nanoformulations are listed in Table 2. 
Gold and platinum nanoparticles have also attracted the attention of researchers due to their 
antibacterial activity (132, 133). Several research groups studied the cytotoxicity of gold 
nanoparticles in different cell types (134, 135). It was shown that citrate-capped gold 
nanoparticles were not cytotoxic to baby hamster kidney cells and human hepatocellular 
liver carcinoma cells, but cytotoxic to human carcinoma cells at certain concentrations (135). 
Despite all research data about the toxicity of gold nanoparticles, still more research for 
better understanding of gold nanoparticles toxicity is reqired. Recently, Wang et al prepared 
16 nm gold nanospheres stabilized with citrate ions and their antimicrobial activity was 
tested against Salmonella typhi bacteria strain TA 102 (133). The results showed that gold 
nanoparticles are not mutagenic or toxic in Salmonella, but is photomutagenic to the bacteria. 
The photomutogenicity was due to the presence of citrate and Au3+ ions used during the 
preparation of gold nanoparticles. Their final results showed that although there was a good 
surface interaction between gold nanoparticles and the bacteria, the gold nanoparticles were 
not able to penetrate into the bacteria. 
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Type of nanoparticle Type of Salmonella Reference 
ASAP Nano-silver Solution Salmonella typhi (136) 
silver colloid nanoparticles Salmonella enteric (137) 
silver–silicon dioxide hybrid Salmonella enteric (137) 
ZnO nanoparticles Salmonella typhimurium (138) 
Spherical silver nanoparticles Salmonella typhimurium (139) 
Zinc oxide QuantumDots SalmonellaEnteritidis (140) 
Silver nanoparticles Salmonella typhi (141) 
Silver nanoparticles Salmonella typhimurium (142) 
Silver bionanoparticles Salmonella typhi (143) 
Silver bionanoparticles Salmonella paratyphi (144) 
TiO2 nanoparticles Salmonella typhimurium (145) 
ZnO nanoparticles Salmonella typhimurium (145) 
Silver nanoparticles Salmonella typhus (146) 
Iron nanoparticles Salmonella paratyphi (147) 
 silver nanoparticles Not specified (148) 
Silver Nanoparticles Salmonella typhimurium (149) 
Silver bionanoparticles Salmonella typhi (150) 
Ag–SiO2 anoparticles Salmonella typhimurium (151) 
Zn1-xTixO (x = 0, 0.01, 0.03 and 0.05) 
nanoparticles 
Salmonella typhi (152) 
platinum nanoparticles Salmonella Enteritidis (153) 
CuO nanoparticles Salmonella paratyphi (154) 
Table 2. Various metal naoparticles used against different microbes  
Similar study was carried out on gold and platinum nanoparticles (132) and the results 
showed that gold nanoparticles can interact with Salmonella Enteritidis but did not penetrate 
the bacterial cell, whereas platinum nanoparticles were observed inside bacterial cells due to 
binding to DNA. They concluded that gold nanoparticles can be used alongside with 
bacteria to deliver the nanoparticles to specific points in the body for targeted delivery. 
A major controversy with metal nanoparticles is that whether they are toxic to bacteria or 
bacteria develops resistance mechanism against these nanoparticles. If the former is true, 
there might be a devastating effect to the ecosystem which will lead to a global 
destabilization. Nanoparticles have a greater potential to travel through an organism and 
could be more toxic due to their larger surface area and specific structural/chemical 
properties. 
Although the evolution of nanotechnology is about to bring various advantages to our 
lives over conventional formulations but the lung toxicity of metal nanoparticles (155) 
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should be carefully considered as these nanoparticles are very small and light, and they 
have larger surface area with a greater potential to travel through an organism or tissues 
(156). These small particles can travel via nasal nerves to the brain (156, 157). It has been 
shown that most of metallic nanoparticles such as TiO2, Ag, Al, Zn, Ni exhibit cellular 
toxicity on human alveolar epithelial cells (158). The results reported by Park et al (158) 
showed that these metal nanoparticles could damage the cell directly or indirectly. The 
cell damage is probably dependent on the size, structure, and composition of the 
nanoparticles, yet more studies are needed for better understanding of the toxicity 
mechanism of the metal nanoparticles. 
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